The listed, delisted, and sustainability of therapeutic medicines for dementia patients: the study is specific to South Korea

Abstract

The Dementia Management Act (DMA) came into effect on August 4, 2011, in South Korea. Diagnosis and medication were rapidly performed for dementia in a short time. We investigated the cardiac effects of increased drug prescription following DMA. We observed a correlation between Alzheimer’s disease (AD) and anti-AD drug (AAD) groups from 2010 to 2019 on the National Health Insurance System (NHIS) of South Korea. This study investigated the increase and decrease in deaths of AD patients with AAD. We analysed the mortality per 100,000 population with the R2 Calculator. Moreover, we made the up or down datum line for the simple decision on the listed, delisted, and sustainable drug examined by a linear equation and R2. We observed that life expectancy was diminished by AAD in Sorokdo National Hospital. In the NHIS, donepezil and rivastigmine increased the number of deaths decided on R2 > 0.75. Memantine was sustainable. We could not decide on galantamine because it is one of the other groups. We made a straightforward decision-maker of delisted, listed, or sustainable criteria based on mortality and datum line.

The study of whether acquired Mendelian diseases are the origin of Alzheimer’s disease from viral respiratory diseases.

“…The War Against Dementia and DMA encouraged the prescription of AAD. It randomized the EDI code-based cohort studies, tested the cohort in a completely blinded state, and provided de nite causality 7 .…”

“…The factor in the AA equation consisted of the dapsone-taking group and the AAD-taking AD group 7 . Through its acetylation capacity, dapsone inhibits the activation of both IFN-1 and NF-κB by targeting cyclic GMP-AMP synthase (cGAS) 45 .…”

“…The Dementia Management Act (DMA) in South Korea was enacted in August 2011 after declaring the "Warning against Dementia in 2008". From 2012 to 2019, Donepezil, rivastigmine, risperidone and quertiapine increased the number of deaths based on R 2 > 0.75 7 . Acetylation and excess acetylcholine (ACh) affect viral respiratory diseases (VRDs), bronchitis, and chronic obstructive pulmonary disease (COPD) 1 .…”

Dapsone is an anticatalysis for Alzheimer’s disease exacerbation

“…It becomes severe before noticeable symptoms appear and cannot be cured by any medicines and therapies. Neuropsychiatric symptoms (NPS) may be highly variable during AD and are considered core AD features rather than merely risk factors for its development ( Loeffler, 2021 ; Lee, 2022 ). The prevalence rates for NPS in AD patients are apathy (49%), depression (42%), aggression (40%), anxiety (39%), sleep disorder (39%), irritability (36%), appetite disorder (34%), aberrant motor behavior (32%), delusion (31%), disinhibition (17%), hallucination (16%), and euphoria (7%) ( Loeffler, 2021 ; Lee, 2022 ).…”

“…Neuropsychiatric symptoms (NPS) may be highly variable during AD and are considered core AD features rather than merely risk factors for its development ( Loeffler, 2021 ; Lee, 2022 ). The prevalence rates for NPS in AD patients are apathy (49%), depression (42%), aggression (40%), anxiety (39%), sleep disorder (39%), irritability (36%), appetite disorder (34%), aberrant motor behavior (32%), delusion (31%), disinhibition (17%), hallucination (16%), and euphoria (7%) ( Loeffler, 2021 ; Lee, 2022 ). Diverse clinical factors reflect the differential involvement of a common core temporoparietal and frontal network that is vulnerable to AD progression ( Warren et al., 2012 ), which is associated with individual genetic influences.…”